No therapy currently addresses tau pathology directly
In the long struggle to slow one of humanity's most feared diseases, two research teams spanning opposite coasts have received a $6.9 million federal grant to bring a promising compound closer to human testing. CNDR-51997, developed jointly by UC San Diego and the University of Pennsylvania, has shown in animal models the rare ability to address both of Alzheimer's defining protein pathologies — amyloid-beta and tau — at once. Where current approved therapies leave tau pathology untouched, this compound reaches further, and its potential extends to an entire family of neurological diseases for which almost no disease-modifying treatments exist. The next three years will test whether that promise can survive the rigors required before it reaches the people who need it most.
- Millions living with Alzheimer's and related tauopathies have no treatment that addresses tau pathology — a gap this compound is specifically designed to close.
- CNDR-51997 disrupts the usual either/or logic of Alzheimer's drug development by reducing both amyloid-beta plaques and tau tangles simultaneously in mouse models.
- The $6.9 million NIH grant sets a three-year clock ticking on the safety studies the FDA requires before any human trials can begin.
- The research teams are aiming to file an Investigational New Drug application by the grant's end, the formal threshold that would unlock Phase 1 clinical trials.
- Beyond Alzheimer's, the compound's tau-targeting mechanism could matter for frontotemporal degeneration, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies with almost no treatment options.
The National Institute on Aging has awarded $6.9 million to two research teams — Carlo Ballatore at UC San Diego and Kurt Brunden at the University of Pennsylvania — to advance a jointly developed Alzheimer's compound through its final preclinical stages. The drug, CNDR-51997, drew attention in mouse studies by doing something no currently approved therapy does: reducing both amyloid-beta plaques and tau pathology at the same time. The two treatments already on the market, lecanemab and donanemab, address only amyloid deposits, leaving tau — and the neuronal collapse it causes — untreated.
Tau normally stabilizes the microtubule scaffolding inside neurons. When it detaches, as it does in Alzheimer's and related diseases, those structures collapse, cutting off the neuron's ability to transport essential proteins and nutrients. The result is a cascade toward cell death. CNDR-51997 was able to interrupt that process in animal models, restoring balance across both pathological fronts.
The three-year grant will fund the safety studies required by the FDA before human testing can begin, with the team targeting an Investigational New Drug application by the grant's conclusion. Approval would open the door to Phase 1 trials. Brunden noted that the unmet need extends well beyond Alzheimer's — conditions like frontotemporal lobar degeneration, progressive supranuclear palsy, and chronic traumatic encephalopathy all share the same tau pathology and have almost no disease-modifying options. The road from mouse models to patients remains long, but this grant marks a deliberate step toward closing a gap that has persisted in neurology for decades.
Two research teams at opposite coasts have just received a substantial vote of confidence from the National Institute on Aging. Carlo Ballatore at UC San Diego and Kurt Brunden at the University of Pennsylvania will share a $6.9 million grant to shepherd a new Alzheimer's compound through the final preclinical hurdles before human testing can begin.
The compound, called CNDR-51997, emerged from a joint drug discovery effort between the two universities. In recent studies using mouse models of Alzheimer's disease, it demonstrated something noteworthy: it reduced both of the hallmark protein tangles that characterize the disease—amyloid-beta plaques and tau pathology. That dual action matters because the two approved Alzheimer's treatments on the market today, lecanemab and donanemab, target only the amyloid deposits. No therapy currently available addresses tau pathology directly, leaving a significant gap in treatment options.
Tau is normally a stabilizing protein that keeps microtubules—the cellular scaffolding inside neurons—organized and functional. In Alzheimer's disease and related conditions, tau detaches from these structures, causing them to collapse. When microtubules fall apart, the neuron loses its ability to transport proteins and nutrients along its long extensions, a process called axonal transport. This breakdown cascades into neuronal death. In the mouse studies, CNDR-51997 was able to restore this balance, correcting both the amyloid and tau problems simultaneously.
The three-year grant will fund the safety studies the FDA requires before any drug can be tested in humans. If those studies go well, the research team plans to submit an Investigational New Drug application by the end of the grant period. Approval of that application would open the door to Phase 1 clinical trials—the first time the compound would be given to people. Ballatore described the moment as urgent: Alzheimer's remains a devastating disease with very few effective treatments, and the preclinical data suggest CNDR-51997 could help.
The potential reach extends beyond Alzheimer's itself. Several other neurological conditions share the same tau pathology problem—frontotemporal lobar degeneration, progressive supranuclear palsy, corticobasal degeneration, Pick's disease, and the tau tangles that accumulate after traumatic brain injury and chronic traumatic encephalopathy. These diseases, collectively called tauopathies, have almost no disease-modifying treatments available. Brunden emphasized that the unmet need in this broader category of tau-related diseases is enormous, and CNDR-51997's ability to address tau could matter for all of them, not just Alzheimer's.
The path from mouse models to human patients is long and uncertain. But this grant represents a concrete step forward for a compound that addresses a genuine gap in the therapeutic landscape. The next three years will determine whether CNDR-51997 can clear the safety hurdles and move into the clinic.
Citas Notables
Alzheimer's is a devastating disease with very few treatment options, so we are eager to advance CNDR-51997 through the drug development process.— Carlo Ballatore, UC San Diego
There is a great unmet need for disease-modifying drugs for the other tauopathies, and the potential of CNDR-51997 to address tau-related diseases beyond Alzheimer's is another important aspect of its therapeutic promise.— Kurt Brunden, University of Pennsylvania
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this compound targets tau when we already have drugs targeting amyloid?
Because Alzheimer's isn't just one problem. You have two different protein tangles happening in the brain at the same time, and the drugs we have now only address one of them. It's like treating half the disease.
So the mice got better when they treated both?
In the mouse models, yes. The compound reduced both the amyloid plaques and the tau tangles. That's the promising part. But we don't know yet if that will translate to people.
What's tau actually doing in a healthy brain?
It's a stabilizer. It keeps the cell's internal scaffolding organized so nutrients and proteins can move through the neuron. When tau malfunctions, that whole transport system breaks down, and the neuron dies.
And this compound fixes that?
In mice, it did. It restored the balance so the microtubules could function again. But now they need to prove it's safe in humans before they can even try it in patients.
How long will that take?
The grant is for three years. If the safety studies work out, they'll apply to the FDA for permission to start Phase 1 trials by the end of that period. So we're probably looking at several more years before any patient could receive it.
What about those other diseases—the traumatic brain injury ones?
That's the bigger picture. Tau problems show up in a whole family of diseases. If this compound works for Alzheimer's, it might work for all of them. That's why the researchers see this as potentially much larger than just one disease.